26 Nov

Rare ED Texas pharma lawsuit may be a sign of things to come for biosimilars litigation

Recent difficulties obtaining preliminary injunctions against biosimilars in the District of Delaware could see more patentees looking to other venues when filing BPCIA suits, especially against foreign defendants.

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth